Instil Bio (TIL) Competitors

$8.14 +0.12 (+1.50%)

As of 03:11 PM Eastern

TIL vs. UNCY, SGMT, LENZ, VYGR, and IKT

Should you buy Instil Bio stock or one of its competitors? MarketBeat compares Instil Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Instil Bio include Unicycive Therapeutics (UNCY), Sagimet Biosciences (SGMT), LENZ Therapeutics (LENZ), Voyager Therapeutics (VYGR), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry.

How does Instil Bio compare to Unicycive Therapeutics?

Instil Bio (NASDAQ:TIL) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 47.0% of Instil Bio shares are held by company insiders. Comparatively, 10.7% of Unicycive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Instil Bio currently has a consensus price target of $66.00, suggesting a potential upside of 714.11%. Unicycive Therapeutics has a consensus price target of $24.00, suggesting a potential upside of 215.79%. Given Instil Bio's higher probable upside, equities analysts clearly believe Instil Bio is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Instil Bio's return on equity of -39.76% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Unicycive Therapeutics	N/A	-134.69%	-84.51%

Instil Bio has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market.

In the previous week, Unicycive Therapeutics had 18 more articles in the media than Instil Bio. MarketBeat recorded 20 mentions for Unicycive Therapeutics and 2 mentions for Instil Bio. Unicycive Therapeutics' average media sentiment score of 0.59 beat Instil Bio's score of 0.50 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Instil Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Unicycive Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Unicycive Therapeutics has higher revenue and earnings than Instil Bio. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Unicycive Therapeutics	$680K	298.41	-$26.56M	-$2.21	N/A

Summary

Instil Bio and Unicycive Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Instil Bio compare to Sagimet Biosciences?

Instil Bio (NASDAQ:TIL) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

In the previous week, Sagimet Biosciences had 1 more articles in the media than Instil Bio. MarketBeat recorded 3 mentions for Sagimet Biosciences and 2 mentions for Instil Bio. Instil Bio's average media sentiment score of 0.50 beat Sagimet Biosciences' score of 0.03 indicating that Instil Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Instil Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sagimet Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sagimet Biosciences' return on equity of -37.57% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Sagimet Biosciences	N/A	-37.57%	-35.52%

Sagimet Biosciences has higher revenue and earnings than Instil Bio. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Sagimet Biosciences	$2M	116.07	-$51.04M	-$1.34	N/A

Instil Bio currently has a consensus target price of $66.00, indicating a potential upside of 714.11%. Sagimet Biosciences has a consensus target price of $25.75, indicating a potential upside of 261.40%. Given Instil Bio's higher possible upside, equities analysts clearly believe Instil Bio is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by company insiders. Comparatively, 14.7% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Instil Bio has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.6, indicating that its stock price is 260% more volatile than the broader market.

Summary

Sagimet Biosciences beats Instil Bio on 9 of the 14 factors compared between the two stocks.

How does Instil Bio compare to LENZ Therapeutics?

Instil Bio (NASDAQ:TIL) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 47.0% of Instil Bio shares are held by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Instil Bio has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. Instil Bio's return on equity of -39.76% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

Instil Bio presently has a consensus target price of $66.00, indicating a potential upside of 714.11%. LENZ Therapeutics has a consensus target price of $29.80, indicating a potential upside of 290.56%. Given Instil Bio's higher probable upside, equities analysts clearly believe Instil Bio is more favorable than LENZ Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Instil Bio has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Instil Bio has higher earnings, but lower revenue than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
LENZ Therapeutics	$19.09M	12.53	-$82.13M	-$3.60	N/A

In the previous week, LENZ Therapeutics had 1 more articles in the media than Instil Bio. MarketBeat recorded 3 mentions for LENZ Therapeutics and 2 mentions for Instil Bio. Instil Bio's average media sentiment score of 0.50 beat LENZ Therapeutics' score of -0.71 indicating that Instil Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Instil Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LENZ Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative

Summary

Instil Bio beats LENZ Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Instil Bio compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Instil Bio has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Instil Bio's return on equity of -39.76% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
Instil Bio	N/A	-39.76%	-22.38%

In the previous week, Instil Bio had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for Instil Bio and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.76 beat Instil Bio's score of 0.50 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Instil Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Instil Bio has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	5.41	-$119.72M	-$1.97	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

Voyager Therapeutics currently has a consensus target price of $16.50, suggesting a potential upside of 356.43%. Instil Bio has a consensus target price of $66.00, suggesting a potential upside of 714.11%. Given Instil Bio's higher probable upside, analysts plainly believe Instil Bio is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Instil Bio	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by company insiders. Comparatively, 47.0% of Instil Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Voyager Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Instil Bio has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market.

Summary

Instil Bio beats Voyager Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Instil Bio compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and Instil Bio (NASDAQ:TIL) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Inhibikase Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 215.19%. Instil Bio has a consensus price target of $66.00, indicating a potential upside of 714.11%. Given Instil Bio's higher probable upside, analysts clearly believe Instil Bio is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	4 Strong Buy rating(s)	3.13
Instil Bio	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Instil Bio had 1 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 2 mentions for Instil Bio and 1 mentions for Inhibikase Therapeutics. Instil Bio's average media sentiment score of 0.50 beat Inhibikase Therapeutics' score of -0.67 indicating that Instil Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Instil Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 7.3% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 47.0% of Instil Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Inhibikase Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.94, meaning that its stock price is 94% more volatile than the broader market.

Instil Bio's return on equity of -39.76% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Instil Bio	N/A	-39.76%	-22.38%

Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

Summary

Instil Bio beats Inhibikase Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Instil Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TIL vs. The Competition

Export

Metric	Instil Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$55.09M	$3.35B	$6.33B	$12.33B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-1.15	18.89	20.88	25.51
Price / Sales	N/A	279.14	520.50	73.06
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	0.50	6.90	10.01	7.03
Net Income	-$71.37M	$24.18M	$3.54B	$334.92M
7 Day Performance	0.71%	0.77%	0.38%	-0.40%
1 Month Performance	-2.56%	-0.38%	-0.02%	1.07%
1 Year Performance	-50.02%	63.37%	35.07%	34.65%

Instil Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TIL Instil Bio	2.2148 of 5 stars	$8.14 +1.5%	$66.00 +710.8%	-51.2%	$55.19M	N/A	N/A	410	Positive News Earnings Report
UNCY Unicycive Therapeutics	3.3785 of 5 stars	$7.73 -5.2%	$24.00 +210.5%	+29.0%	$217.60M	$680K	N/A	9	Analyst Revision
SGMT Sagimet Biosciences	3.0263 of 5 stars	$6.54 -1.8%	$25.75 +293.7%	+93.9%	$217.02M	$2M	N/A	8	Analyst Forecast
LENZ LENZ Therapeutics	2.4685 of 5 stars	$6.65 -3.6%	$29.80 +348.1%	-74.9%	$216.35M	$19.09M	N/A	110
VYGR Voyager Therapeutics	2.8708 of 5 stars	$3.48 -1.4%	$16.50 +374.1%	+2.9%	$213.29M	$40.37M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TIL) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Instil Bio (TIL) Competitors

TIL vs. UNCY, SGMT, LENZ, VYGR, and IKT

How does Instil Bio compare to Unicycive Therapeutics?

Summary

How does Instil Bio compare to Sagimet Biosciences?

Summary

How does Instil Bio compare to LENZ Therapeutics?

Summary

How does Instil Bio compare to Voyager Therapeutics?

Summary

How does Instil Bio compare to Inhibikase Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TIL vs. The Competition

Instil Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Instil Bio (TIL) Competitors

TIL vs. UNCY, SGMT, LENZ, VYGR, and IKT

How does Instil Bio compare to Unicycive Therapeutics?

Do institutionals & insiders have more ownership in TIL or UNCY?

Do analysts recommend TIL or UNCY?

Is TIL or UNCY more profitable?

Which has more volatility and risk, TIL or UNCY?

Does the media prefer TIL or UNCY?

Which has higher valuation & earnings, TIL or UNCY?

Summary

How does Instil Bio compare to Sagimet Biosciences?

Does the media favor TIL or SGMT?

Is TIL or SGMT more profitable?

Which has stronger earnings and valuation, TIL or SGMT?

Do analysts rate TIL or SGMT?

Do insiders & institutionals hold more shares of TIL or SGMT?

Which has more risk and volatility, TIL or SGMT?

Summary

How does Instil Bio compare to LENZ Therapeutics?

Do insiders & institutionals believe in TIL or LENZ?

Is TIL or LENZ more profitable?

Do analysts recommend TIL or LENZ?

Which has more risk & volatility, TIL or LENZ?

Which has preferable earnings and valuation, TIL or LENZ?

Does the media favor TIL or LENZ?

Summary

How does Instil Bio compare to Voyager Therapeutics?

Is VYGR or TIL more profitable?

Does the media prefer VYGR or TIL?

Which has higher valuation and earnings, VYGR or TIL?

Do analysts rate VYGR or TIL?

Do insiders & institutionals believe in VYGR or TIL?

Which has more volatility and risk, VYGR or TIL?

Summary

How does Instil Bio compare to Inhibikase Therapeutics?

Do analysts rate IKT or TIL?

Does the media prefer IKT or TIL?

Do institutionals and insiders believe in IKT or TIL?

Which has more risk & volatility, IKT or TIL?

Is IKT or TIL more profitable?

Which has better valuation and earnings, IKT or TIL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TIL vs. The Competition

Instil Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools